Contrast agent developer Epix Medical reported first-quarter revenues of $2.1 million, compared with $1.7 million booked in the first quarter of 2001. For the period (end-March 31), the Cambridge, MA-based firm had a net loss of $4.6 million, compared with a net loss of $5 million reported in the first quarter of 2001.
During the first quarter, Epix received $1.3 million from a product development contract with Schering, $413,000 from a patent licensing and royalty agreement from Bracco Imaging, and $423,000 in license fee revenue from Schering and Tyco/Mallinckrodt. In the first quarter of 2001, Epix received $1.3 million from the Schering development contract, and $423,000 in license fee revenue from Schering and Tyco/Mallinckrodt.
By AuntMinnie.com staff writersApril 24, 2002
Related Reading
Epix to raise $30 million, January 16, 2002
Epix revenues climb in Q3, October 19, 2001
Epix, Bracco ink licensing deal, September 25, 2001
Wirth joins Epix Medical board, August 30, 2001
Epix net loss grows in Q2, July 27, 2001
Copyright © 2002 AuntMinnie.com
